Recommended Pages at empr.com

Latuda Dosing Range Updated - MPR

empr.com — “Sunovion announced that the FDA has approved an expanded dose range for Latuda (lurasidone) tablets in the treatment of adult patients with schizophrenia.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 7, 2012 at 6:52 pm By:

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia - MPR

empr.com — “Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 7, 2012 at 5:18 pm By:

eMPR MPR Medical Publisher

Phase 3 Study of #Aripiprazole Intramuscular Depot for the Maintenance Treatment of #Schizophrenia http://t.co/hAN0om32

3 weeks ago...

FDA Issues Complete Response Letter to NDA for Adasuve - MPR

empr.com — “Alexza Pharmaceuticals announced that it has received a complete response letter from the FDA regarding its New Drug Application (NDA) for Adasuve (Staccato loxapine) inhalation powder, 5mg and 10mg, for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 7, 2012 at 3:35 pm By:

Phase 3 Trial Update of Latuda for Bipolar I Depression - MPR

empr.com — “Dainippon Sumitomo Pharma announced results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of Latuda (lurasidone; Sunovion) as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 7, 2012 at 2:27 pm By:

RECALL: Franck's Compounding Triamcinolone Acetonide Recall - MPR

empr.com — “Franck's Compounding Pharmacy has recalled one additional lot of triamcinolone acetonide PF 80mg/mL.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 4, 2012 at 7:31 pm By:

Phase 3 Study Update of 4-Factor Prothrombin Complex Concentrate for Hemostasis - MPR

empr.com — “CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (eg, warfarin).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 4, 2012 at 6:07 pm By:

Phase 3 Study Update of Gattex for Adult Short Bowel Syndrome - MPR

empr.com — “NPS Pharmaceuticals reported that four additional patients have successfully achieved independence from parenteral nutrition (PN) and intravenous (IV) fluids while on long-term Gattex (teduglutide) therapy in STEPS 2, a 24-month open-label study in adult short bowel syndrome (SBS).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 3, 2012 at 1:42 pm By:

Dymista Approved for Allergic Rhinitis - MPR

empr.com — “Meda announced that the FDA has approved Dymista (azelastine HCl and fluticasone propionate) nasal spray for the treatment of seasonal allergic rhinitis.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 2, 2012 at 2:02 pm By:

QNASL - New Product Releases - MPR

empr.com — “Seasonal and perennial allergic rhinitis.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 2, 2012 at 1:06 pm By:

eMPR MPR Medical Publisher

NEW PRODUCT: Learn more about QNASL for seasonal and perennial allergic rhinitis http://t.co/oo0KDmhl #allergies

4 weeks ago...

Phase 3 Study Update of Quadrivalent Influenza Vaccine in Pediatric Population - MPR

empr.com — “Sanofi Pasteur, the vaccines division of Sanofi Aventis, announced new Phase 3 data for its investigational quadrivalent influenza vaccine (QIV) in children.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 1, 2012 at 6:57 pm By:

Mylan Launches Generic Doryx 150mg - MPR

empr.com — “Mylan announced the launch of Doxycycline hyclate delayed-release (DR) tablets, 150mg, the generic version of Warner Chilcott's Doryx tablets.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 1, 2012 at 2:35 pm By:

AAN: Migraine Prevalence Up in Celiac Disease, IBD Patients - MPR

empr.com — “Patients with celiac disease or inflammatory bowel disease (IBD) and those self-classified with gluten sensitivity (GS) have increased prevalence of migraine.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 30, 2012 at 11:07 pm By:

GlutenFreeBee Gluten Free Bee Patient Expert

AAN: Migraine Prevalence Up in Celiac Disease, IBD Patients - MPR http://t.co/xoavZaPe

4 weeks ago...

Voraxaze Injection Now Available - MPR

empr.com — “Voraxaze Injection Now Available - MPRView full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 30, 2012 at 3:06 pm By:

Stendra Approved for Erectile Dysfunction - MPR

empr.com — “The FDA announced that it has approved Stendra (avanafil; Vivus Inc.) tablets for the treatment of erectile dysfunction.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 30, 2012 at 1:54 pm By:

FDA Issues Complete Response Letter to sBLA for Xgeva - MPR

empr.com — “Amgen announced that it received a complete response letter from the FDA for it supplemental Biologics License Application (sBLA) for Xgeva (denosumab) injection for the treatment of men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 27, 2012 at 4:02 pm By:

 1 2 3 4 Next ›  Last »